227 Westminster N
About Corbin Therapeutics
Corbin Therapeutics is a Montreal-based biotech company, using a unique drug discovery platform to identify and develop novel USP15 inhibitors for treatment of various inflammation diseases, such as multiple sclerosis. This platform includes several in-vitro and in-vivo models for efficient drug screening and confirmation of potential lead candidates.
CEO: Véronique Bougie
CSO: Philippe Gros
5 articles about Corbin Therapeutics
Corbin Therapeutics, headquartered in Montreal, Quebec, was spun out of venture capital company AmorChem.
BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.
University of Dundee And Corbin Therapeutics Collaborate To Discover Novel USP15 Inhibitors
Corbin Therapeutics And Proteorex Therapeutics Announce A Research And Development Collaboration To Discover Novel Ubiquitin-Specific Protease Inhibitors
AmorChem l.p. Spins Out Its Usp15-Deubiquitinylation (Dub) Drug Discovery Platform Into Corbin Therapeutics, With A First 1M$ Seed Investment